Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramipril in Early Alport Syndrome
NCT05133050Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ramipril in Alport syndrome (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Disease progression time up to 240 weeks. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
ramipril
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT05133050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133050.